Share Price:

APNASPENAspen Pharmacare Hldgs21701-219 (-1.00%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Month: March 2013

Aspen increases revenue to R9 billion

JSE Limited listed Aspen Pharmacare Holdings Limited (Apn), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the interim period ended 31 December 2012. Group Performance Revenue from continuing operations increased by 20% to R9.0 billion. Operating profit from continuing operations rose by 24% to R2.5… Continue reading Aspen increases revenue to R9 billion

Renewal of Cautionary Announcement

Shareholders are referred to the cautionary announcement released by Aspen on 4 February 2013 (and subsequent renewals of this cautionary announcement) in which shareholders were advised of discussions between Aspen and MSD, known as Merck in the United States and Canada, in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient… Continue reading Renewal of Cautionary Announcement

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.